Skip to main content

Table 1 Antimicrotubule trials.

From: Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Trial

N randomized/evaluable

Treatment arms (dose) and schedule

Duration

Tannock, 2004 [64]

1006/1006

docetaxel (75 mg/m2) iv q 3 wks prednisone (5 mg) po twice daily dexamethasone (8 mg) at 12, 3, and 1 hr(s) prior to infusion

10 cycles

  

docetaxel (30 mg/m2) iv q wk for 5 wks prednisone (5 mg) po twice daily dexamethasone (8 mg) at 1 hr prior to infusion

5 cycles

  

mitoxantrone (12 mg/m2) iv q 3 wks prednisone (5 mg) po twice daily

10 cycles

Petrylak, 2004 [63]

770/666

docetaxel (60 mg/m2)* iv q 3 wks EMP (280 mg) po thrice daily q 3 wks dexamethasone (20 mg) po thrice daily q 3 wks

12 cycles

  

mitoxantrone (12 mg/m2)* iv q 3 wks prednisone (5 mg) po twice daily q 3 wks

 

Abratt, 2003 [62]

451/414

vinorelbine (30 mg/m2) iv q 3 wks hydrocortisone (40 mg) ± AGM (1000 mg)† daily

to progression

  

hydrocortisone (40 mg) ± AGM (1000 mg)† daily

 

Berry, 2001 [84]

166/NR

paclitaxel (100 mg/m2) iv q 4 wks EMP (280 mg) po thrice daily

NR

  

paclitaxel (100 mg/m2) iv q 4 wks

 

Hudes, 1999 [61]

201/193

vinblastine (4 mg/m2) iv q wk for 6 of 8 wks EMP (600 mg/m2) po daily (2 or 3 divided doses)

to progression

  

vinblastine (4 mg/m2) iv q wk for 6 of 8 wks

 

Iversen, 1997 [65]

131/129

EMP (560 mg) po daily (2 divided doses)

as long as tolerated by patient

  

placebo po daily

 

Johansson, 1991 [66]

105/102

MPA (1000 mg) im daily (d1-15), then im weekly

to progression

  

EMP (280 mg) po twice daily

 

De Kernion, 1988 [67]

220/203

EMP (600 mg/m2) po (3 divided doses)

NR

  

flutamide (0.25 gm) po thrice daily

 

Murphy, 1979 [68]

135/116

EMP (600 mg/m2) po daily (3 divided doses) prednimustine (30 mg) po daily (3 divided doses) q wk

to progression

  

prednimustine (30 mg) po daily (3 divided doses) q wk

 
  1. *Docetaxel could be increased to 70 mg/m2 and mitoxantrone could be increased to 14 mg/m2 if no grade 3 or 4 toxicities were observed in cycle 1; †decision to use AGM was at the discretion of participating centers.
  2. Abbreviations: AGM – aminoglutethimide; d – day; EMP – estramustine phosphate; hr – hour; im – intra muscular; iv – intravenous; mg – milligrams; MPA – medroxyprogesterone acetate; m2 - meters squared; N – number; NR – not reported; po – per oral; q – every; wk(s) – week (s).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us